



22 May 2014

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

### Results of Annual General Meeting on 22 May 2014

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out below.

#### Item 1 – Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
24,336,652	29,762	5,000	-

This resolution was passed on a show of hands.

#### Item 2 – Re-Election of Mr Vanda Gould

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
24,344,609	19,260	7,545	-

This resolution was passed on a show of hands.

#### Item 3 – Election of Mr Henry Townsing

The instructions given to validly appointed proxies in respect of the resolution were as follows:

In favour	Against	Abstain	Proxy's discretion
24,354,102	16,800	512	-

This resolution was passed on a show of hands.



#### **Item 4 – Share Buy-back**

The instructions given to validly appointed proxies in respect of the resolution were as follows:

<b>In favour</b>	<b>Against</b>	<b>Abstain</b>	<b>Proxy's discretion</b>
24,354,614	-	16,800	-

This resolution was passed on a show of hands.

James McBrayer  
**Managing Director and Company Secretary**

**For more information, please contact either:**

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411



---

## **Background**

### **Cyclopharm Limited**

Cyclopharm is a radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

### **Technegas**

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700°C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

### **Positron Emission Tomography (PET)**

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease at a metabolic level. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed at a much earlier stage.